Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04138-5
Abstract: Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been established. In… read more here.
Keywords: combination; resistant cells; dm1; trastuzumab emtansine ... See more keywords
Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01408-7
Abstract: Trastuzumab emtansine (Kadcyla®), an antibody–drug conjugate of trastuzumab (Herceptin®) connected by a thioether linker to the microtubule inhibitor DM1 (a cytotoxic derivative of maytansine), provides direct intracellular delivery of the potent cytotoxin DM1 to HER2-overexpressing… read more here.
Keywords: trastuzumab emtansine; breast cancer; her2; emtansine ... See more keywords
A Phase II Study of Trastuzumab Emtansine in HER2‐Positive Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2017.10.032
Abstract: &NA; Trastuzumab emtansine (T‐DM1), an anti–erb‐b2 receptor tyrosine kinase 2 (HER2) antibody‐drug conjugate, has been shown to significantly improve survival in HER2‐positive breast cancer. We report a phase II trial of T‐DM1 monotherapy in relapsed… read more here.
Keywords: her2 positive; trastuzumab emtansine; ihc; cancer ... See more keywords
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0635-y
Abstract: The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders… read more here.
Keywords: dm1; trastuzumab emtansine; resistance; emtansine dm1 ... See more keywords
Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry
Sign Up to like & getrecommendations! Published in 2018 at "mAbs"
DOI: 10.1080/19420862.2018.1494487
Abstract: ABSTRACT Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. T-DM1 is composed of the humanized monoclonal antibody trastuzumab connected to a maytansine derivative cytotoxic drug, via a nonreducible… read more here.
Keywords: high resolution; trastuzumab emtansine; mass; resolution accurate ... See more keywords
Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001369
Abstract: The erb-b2 receptor tyrosine kinase 2 (ERBB2), also known as HER2, has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers, and ERBB2-targeted therapies are standard for ERBB2-positive breast and gastric… read more here.
Keywords: lung adenocarcinoma; trastuzumab emtansine; lung; treatment ... See more keywords
Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000033677
Abstract: Human epidermal growth factor receptor 2 (HER2)-targeting therapies have become crucial in the management of HER2-positive breast cancer. Trastuzumab emtansine (T-DM1) is a microtubule inhibitor and HER2-targeted antibody conjugate. T-DM1 resistance is most likely influenced… read more here.
Keywords: trastuzumab emtansine; her2; emtansine dm1; breast cancer ... See more keywords
Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21654
Abstract: D EAR E DITOR , A 46-year-old woman with invasive lobular carci-noma of the breast presented to the oncodermatology clinic for a growth on the ventral tongue that developed approxi-mately 6 months after initiation of… read more here.
Keywords: trastuzumab emtansine; emtansine dm1; mucosal haemangioma; treatment ... See more keywords
Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning-measured Spleen Volume at CT.
Sign Up to like & getrecommendations! Published in 2022 at "Radiology"
DOI: 10.1148/radiol.220536
Abstract: Background Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for use in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Case reports have suggested an association between T-DM1 and portal hypertension. Purpose To evaluate… read more here.
Keywords: spleen volume; trastuzumab emtansine; hypertension; portal hypertension ... See more keywords
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3980
Abstract: On May 3, 2019, the FDA granted regular approval to ado-trastuzumab emtansine (KADCYLA), for the adjuvant treatment of patients with HER2-positive early-breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane-based chemotherapy and trastuzumab-based… read more here.
Keywords: ado trastuzumab; treatment; trastuzumab emtansine;
Interstitial pneumonitis associated with trastuzumab emtansine
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155218813716
Abstract: Trastuzumab emtansine is an antibody–drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3–4 toxicities are rare. Pulmonary complications were rarely… read more here.
Keywords: pneumonitis associated; trastuzumab emtansine; associated trastuzumab; interstitial pneumonitis ... See more keywords